Related references
Note: Only part of the references are listed.Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study
Hildur Helgadottir et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
The association between tumor mutational burden and prognosis is dependent on treatment context
Cristina Valero et al.
NATURE GENETICS (2021)
Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
April A. N. Rose et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study
Tao Li et al.
INVESTIGATIONAL NEW DRUGS (2020)
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial
Bixia Tang et al.
CLINICAL CANCER RESEARCH (2020)
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
Alexander M. M. Eggermont et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2020)
Strength of immune selection in tumors varies with sex and age
Andrea Castro et al.
NATURE COMMUNICATIONS (2020)
Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity
Felicity Newell et al.
NATURE COMMUNICATIONS (2020)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
Lu Si et al.
TRANSLATIONAL ONCOLOGY (2019)
Chinese guidelines for diagnosis and treatment of melanoma 2018 (English version)
CHINESE JOURNAL OF CANCER RESEARCH (2019)
Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma
Jenny H. J. Lee et al.
PIGMENT CELL & MELANOMA RESEARCH (2018)
Trends in incidence of thick, thin and in situ melanoma in Europe
L. Sacchetto et al.
EUROPEAN JOURNAL OF CANCER (2018)
Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)
Yingcheng Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab
Christopher G. England et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Andrea Botticelli et al.
ONCOTARGET (2017)
Radiosynthesis and preclinical PET evaluation of 89Zr-nivolumab (BMS-936558) in healthy non-human primates
Erin L. Cole et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy
Adi Nosrati et al.
BRITISH JOURNAL OF CANCER (2017)
Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients
Leila Khoja et al.
BRITISH JOURNAL OF CANCER (2016)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
International trends in the incidence of malignant melanoma 1953-2008uare recent generations at higher or lower risk?
Friederike Erdmann et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991
Alexander M. M. Eggermont et al.
EUROPEAN JOURNAL OF CANCER (2012)
Share Paper
